Group 1: Market Movements - Baoji Pharmaceutical-B (02659) surged over 3.2% amid its debut on the Hong Kong Stock Exchange, closing up 138.82% on its first day, with a market capitalization exceeding HKD 20 billion [1] - New Energy (01799) and Xinyi Solar (00968) saw declines of 3.01% and 3.67% respectively, as the photovoltaic sector faced weakness, with rumors of a 30 billion yuan investment for capacity storage by major companies [1] - Xpeng Motors-W (09868) and Li Auto-W (02015) dropped 4.88% and 2.67% respectively, following data from the China Association of Automobile Manufacturers indicating a month-on-month increase in production and sales [1] Group 2: Company-Specific News - Bolek Vision Cloud-B (02592) experienced a significant drop of nearly 15%, having previously doubled in price over 10 trading days, as it announced a new drug trial application to the FDA [2] - Hu Shang Ayi (02589) rose nearly 6% as Nayuki Tea expanded into the U.S. market, enhancing the international presence of Chinese tea brands [2] - Gold stocks fell sharply, with Zijin Mining (02899) and Shandong Gold (01787) declining by 4.29% and 4.94% respectively, following a report on the Bloomberg Commodity Index's upcoming rebalancing [2] Group 3: Cryptocurrency and Technology - Cryptocurrency ETFs faced significant declines, with notable drops in Bitcoin and Ethereum-related funds, as Bitcoin fell 3.3% from its record high, reflecting market pressures amid weak liquidity [3] - Oracle (ORCL.US) continued its downward trend, dropping 2.66% due to delays in delivering AI data centers for OpenAI, attributed to labor and material shortages [6] - Nvidia (NVDA.US) saw a slight increase of 0.73% after announcing the release of its third-generation language model, aimed at writing and programming tasks [6]

Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. Eli Lilly’s Mounjaro Added to China’s National Health Insurance for Diabetes In another development, Eli Lilly and Company (NYSE:LLY) announced on December 11 positive topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the efficacy a ...

Market Performance - On Monday, major U.S. stock indices collectively declined, with the Dow Jones down 0.09% at 48,416.56 points, the Nasdaq down 0.59% at 23,057.41 points, and the S&P 500 down 0.16% at 6,816.51 points [1][2]. Tesla Highlights - Tesla's stock rose over 3%, reaching a nearly one-year high, with a market value increase of over $53 billion in one night [1][4]. - CEO Elon Musk's net worth surpassed $600 billion, making him the first person in history to achieve this milestone [4]. iRobot Situation - iRobot's stock plummeted over 72% after the company filed for bankruptcy protection, planning to be taken over by its main Chinese supplier and manufacturer, leading to its delisting [1][5]. Chinese Stocks Performance - The Nasdaq Golden Dragon China Index fell by 2.17%, with notable declines in stocks such as Baidu (down nearly 5%) and Alibaba (down over 3%) [1][7]. Nasdaq Trading Mechanism - Nasdaq plans to submit a proposal to the SEC to introduce a near-around-the-clock trading mechanism, extending trading hours from 16 to 23 hours per week [1][14]. - The new trading schedule would include two trading periods: a daytime session starting at 4 AM and ending at 8 PM, and a night session from 9 PM to 4 AM [14][15].

Group 1 - Broadcom shares fell over 5%, while Apple and Amazon rose over 1%, and Tesla increased by over 3%, adding $53.7 billion (approximately 378.6 billion RMB) to its market value [1] - Elon Musk's net worth reached $677 billion, making him the first person in history to surpass the $600 billion mark, previously no one had crossed $500 billion [3] - iRobot officially declared bankruptcy with a stock value of zero after finalizing its restructuring plan on December 15, resulting in a 72.69% drop in its shares [3] Group 2 - The Nasdaq Golden Dragon China Index fell by 2.17%, with major Chinese stocks declining; Baidu dropped nearly 5%, and Alibaba, Xpeng Motors, and others fell over 3% [5] - WTI crude oil futures decreased by 1.08% to $56.82 per barrel, while Brent crude oil futures fell by 0.92% to $60.56 per barrel [6] - Bitcoin fell below $86,000 for the first time in two weeks, dropping 3.3% to $85,578, approximately 30% down from its record high of over $126,000 [6][7] Group 3 - Over the past 24 hours, more than 190,000 traders were liquidated, resulting in a total loss of $670 million (approximately 4.7 billion RMB) [9] - The New York Federal Reserve's manufacturing index unexpectedly shrank to -3.9 in December, indicating a contraction in economic activity, significantly below the expected median of 10 [11][13] - Federal Reserve Governor Milan suggested that the current monetary policy is too tight and advocated for a faster pace of rate cuts, citing signs of a cooling labor market [13]

Group 1: Tesla - Tesla's stock rose by 3.56%, reaching a nearly one-year high with a trading volume of $54.109 billion [1][7] - The company is piloting a Robotaxi service in Austin without a safety driver, confirming the shift towards autonomous driving [1][8] - Wedbush predicts Tesla's market value will reach $3 trillion by the end of 2026, with Full Self-Driving (FSD) penetration potentially exceeding 50% [1][8] - Analyst Dan Ives states that Tesla is advancing towards an "AI revolution," with autonomous driving and robotics as core focus areas by 2026 [1][8] Group 2: Nvidia - Nvidia's stock increased by 0.73%, with a trading volume of $28.936 billion [1][10] - The company announced the launch of its new flagship open-source model series, Nemotron 3, which boasts improvements in speed, cost-effectiveness, and intelligence [1][10] Group 3: Broadcom - Broadcom's stock fell by 5.59%, with a trading volume of $22.525 billion, marking a three-day cumulative decline of 17.7% [2][9] - CICC maintains an "outperform" rating for Broadcom, with a target price of $475, citing strong AI ASIC revenue and a backlog of $73 billion [2][9] - The firm has raised its earnings forecast for FY26/FY27 due to increased visibility in revenue from AI computing and networking [2][9] Group 4: Amazon and Meta Platforms - Amazon's stock declined by 1.61%, with a trading volume of $10.253 billion, marking three consecutive days of decline [3][10] - Meta Platforms' stock rose by 0.59%, with a trading volume of $9.842 billion; the company is offering up to $100 million in signing bonuses for engineers and $250 million for top AI researchers [3][10] Group 5: Oracle - Oracle's stock decreased by 2.66%, with a trading volume of $8.047 billion; the company is facing scrutiny over its aggressive AI investment strategy [3][10] - Analysts expect Oracle's bonds to remain under pressure as the company recorded its largest stock drop in nearly 11 months [3][10] Group 6: Eli Lilly - Eli Lilly's stock rose by 3.38%, with a trading volume of $4.902 billion; the approval process for its experimental oral weight-loss drug, orforglipron, is expected to accelerate [4][11] - The potential approval date may be moved up to March 2026 from mid-May 2026, enhancing Eli Lilly's competitive position in the growing weight-loss market [4][11] Group 7: ServiceNow - ServiceNow's stock fell by 11.54%, with a trading volume of $4.555 billion; the company is in advanced talks to acquire cybersecurity startup Armis for up to $7 billion [4][11] - The deal, if completed, would be ServiceNow's largest acquisition to date, although there are risks of negotiation breakdowns or competing bids [4][11] Group 8: Strategy - Strategy's stock dropped by 8.14%, with a trading volume of $4.089 billion, following a decline in Bitcoin prices [4][12] - The CEO confirmed that the company's Bitcoin accumulation strategy is ongoing and will continue through the end of 2025 [4][12]

Can anything stop this high-flying drugmaker?Eli Lilly (LLY +3.44%) recently made history. It became the first healthcare stock to reach a market cap of $1 trillion. Although it has since dipped below that, the company's performance over the past few years has been phenomenal, and there could be more of that in store next year. How will 2026 unfold for Eli Lilly? Let's look at two potential developments to watch out for.1. A pair of new launches in weight managementEli Lilly has now firmly established itsel ...

Eli Lilly & Co. (NYSE:LLY) 's dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still underestimating just how much growth lies ahead.On Monday, the bank’s analyst Jason Gerberry reiterated a Buy rating on the stock, trimming his price objective slightly from $1,286 to $1,268. The adjustment wasn't about waning confidence. The stock was trading around $1,055 Monday.Instead, Gerberry said there remains "room for stock upside" as Lilly cont ...

Core Viewpoint - Eli Lilly & Co. is positioned strongly in the obesity therapeutics market, with Bank of America believing that the growth potential is still underestimated by the market [1][10] Group 1: Stock Performance and Analyst Ratings - Bank of America analyst Jason Gerberry reiterated a Buy rating on Eli Lilly, slightly adjusting the price target from $1,286 to $1,268, while the stock was trading around $1,055 [1] - There is perceived "room for stock upside" as Lilly continues to execute key obesity launches and mitigate risks associated with new therapies [2] Group 2: Orfoglipron Launch and Market Potential - Orfoglipron, Lilly's oral GLP-1 weight-loss pill, is expected to launch in the second half of 2026, following an expedited regulatory review [3] - The oral formulation of Orfoglipron eliminates refrigeration and injection barriers, making it more appealing to patients [3] - Bank of America forecasts $3 billion in Orfoglipron revenue for 2026, significantly higher than consensus estimates of around $1 billion [4] Group 3: Government Access and Pricing Strategy - A recent U.S. government agreement allows Medicare and Medicaid beneficiaries to access obesity medications at a fixed net price of $245, translating to approximately $50 per month for patients [6] - This agreement is seen as a strategic trade-off that may pressure headline pricing but is expected to drive higher patient volumes [6][7] Group 4: Long-Term Growth and Competitive Landscape - The long-term growth story for Lilly remains intact, with several upcoming data readouts expected to influence future developments [8] - There is particular opportunity in treating "super-obese" patients, which could support high-single-digit billion peak sales [9] - Bank of America does not anticipate that Novo Nordisk's upcoming head-to-head obesity study will significantly impact Lilly's Zepbound position [9] Group 5: Overall Market Outlook - Lilly's sales growth trajectory over the next five to seven years supports a premium multiple, driven by leadership in obesity, upcoming oral GLP-1 launches, and expanding access channels [10] - As Orfoglipron approaches its launch, the market may still be underestimating the potential scale of Lilly's next chapter in obesity therapeutics [10]

Core Viewpoint - Eli Lilly's experimental oral weight loss drug orforglipron is expected to have its approval process expedited, potentially receiving a regulatory decision from the FDA by the end of March 2026, earlier than the previously planned mid-May 2026 date, which is significant for the company's competitive position in the rapidly growing weight loss drug market [1] Group 1 - Eli Lilly's stock rose over 2% following the news of the expedited approval process for orforglipron [1] - The potential earlier approval date could enhance Eli Lilly's competitive standing in the weight loss drug market [1]

据媒体援引相关文件报道，FDA官员正推动审评人员加快对该药物的评估速度。根据文件披露，FDA曾 考虑将其"加速审评凭证(expedited voucher)"项目下的受理评估时间，从目前的60天缩短至1周，虽然最 终方案调整为两至三周，但仍将显著快于原有流程。 审批节奏的加快，意味着orforglipron的潜在获批时间，可能由原计划的2026年5月中旬提前至3月底。这 对礼来在快速增长的减肥药市场中的竞争地位具有重要意义。 周一，礼来(LLY.US)股价走高，截至发稿，该股涨超2%，报1049.84美元。消息面上，该公司旗下的实 验性口服减肥药orforglipron的审批进程有望明显提速，最快可能在2026年3月底获得美国食品药品监督 管理局(FDA)的监管决定。 ...